The efficacy and safety of dapagliflozin in non-diabetic patients with chronic kidney disease
10.3760/cma.j.cn441217-20241212-01230
- VernacularTitle:达格列净对不伴糖尿病慢性肾脏病患者的疗效与安全性
- Author:
Yuhua FENG
1
;
Jingyu DOU
;
Zhen ZHANG
;
Lu WEN
;
Qianqian LI
;
Yan SU
;
Genyang CHENG
Author Information
1. 郑州大学第一附属医院肾内科，郑州 450052
- Publication Type:Journal Article
- Keywords:
Renal insufficiency, chronic;
Sodium-glucose transporter 2 inhibitors;
Treatment outcomes;
Dapagliflozin;
Safety
- From:
Chinese Journal of Nephrology
2025;41(11):855-858
- CountryChina
- Language:Chinese
-
Abstract:
A total of 269 non-diabetic chronic kidney disease (CKD) patients were enrolled in this study. Among them, 175 patients (65.1%) were assigned to the control group and received conventional therapy with maximally tolerated doses of renin-angiotensin-aldosterone system inhibitors, while 94 patients (34.9%) were assigned to the dapagliflozin group and received oral dapagliflozin 10 mg/day in addition to the conventional therapy. The results showed that the urine protein quantity in the dapagliflozin group was lower than those in the control group at 3, 6, 12, 18, and 24 months of follow-up (all P<0.05), and the blood albumin level was higher than those in the control group at 18 and 24 months of follow-up (all P<0.05). The Kaplan-Meier survival curve analysis results showed that the cumulative renal survival rate of the dapagliflozin group was significantly higher than that of the control group (Log-rank test, χ2=5.078, P=0.024). Multivariable Cox regression analysis results revealed that using dapagliflozin was independently associated with a reduced risk of the composite endpoint in non-diabetic CKD patients ( HR=0.400, 95% CI 0.163-0.983, P=0.046). There was no statistical difference in adverse reactions between the two groups (all P>0.05). It is indicated that dapagliflozin has a renal protective effect independent of hypoglycemic action and good safety.
